Dr. McDermott on Immunotherapy-Related AEs in RCC – OncLive
OncLive |
Dr. McDermott on Immunotherapy-Related AEs in RCC
OncLive While grade 3/4 complications are relatively less common at approximately 20% of patients, there are some who can die from toxicities associated with immunotherapy if they are not caught and managed quickly. Additionally, he cautions, early … |
